Evidence map›Paper›PMID 38903495›Full record

ArticleFrontiers in immunology2024

Clinical and genetic characteristics of

Johanna Matull, Jan-Malte Placke, Georg Lodde, Anne Zaremba, Jochen Utikal, Patrick Terheyden, Claudia Pföhler, Rudolf Herbst, Alexander Kreuter, Julia Welzel and 11 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Johanna MatullDepartment of Dermatology, University Hospital Essen, University of Duisburg-Essen, Germany & German Cancer Consortium (Deutsches Konsortium für Translationale Krebsforschung, DKTK), Essen, Germany.
Jan-Malte PlackeDepartment of Dermatology, University Hospital Essen, University of Duisburg-Essen, Germany & German Cancer Consortium (Deutsches Konsortium für Translationale Krebsforschung, DKTK), Essen, Germany.
Georg LoddeDepartment of Dermatology, University Hospital Essen, University of Duisburg-Essen, Germany & German Cancer Consortium (Deutsches Konsortium für Translationale Krebsforschung, DKTK), Essen, Germany.
Anne ZarembaDepartment of Dermatology, University Hospital Essen, University of Duisburg-Essen, Germany & German Cancer Consortium (Deutsches Konsortium für Translationale Krebsforschung, DKTK), Essen, Germany.
Jochen UtikalSkin Cancer Unit, German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), Heidelberg, Germany.
Patrick TerheydenDepartment of Dermatology, University Hospital Schleswig-Holstein, Lübeck, Germany.
Claudia PföhlerDepartment of Dermatology, Saarland University Medical School, Homburg, Germany.
Rudolf HerbstSkin Cancer Unit, Helios Klinikum Erfurt, Erfurt, Germany.
Alexander KreuterDepartment of Dermatology, Venereology and Allergology, Helios St. Elisabeth Hospital Oberhausen, University Witten/Herdecke, Oberhausen, Germany.
Julia WelzelDepartment of Dermatology and Allergology, University Hospital Augsburg, Augsburg, Germany.
Julia KretzDepartment of Dermatology, University Hospital Essen, University of Duisburg-Essen, Germany & German Cancer Consortium (Deutsches Konsortium für Translationale Krebsforschung, DKTK), Essen, Germany.
Inga MöllerDepartment of Dermatology, University Hospital Essen, University of Duisburg-Essen, Germany & German Cancer Consortium (Deutsches Konsortium für Translationale Krebsforschung, DKTK), Essen, Germany.
Antje SuckerDepartment of Dermatology, University Hospital Essen, University of Duisburg-Essen, Germany & German Cancer Consortium (Deutsches Konsortium für Translationale Krebsforschung, DKTK), Essen, Germany.
Annette PaschenDepartment of Dermatology, University Hospital Essen, University of Duisburg-Essen, Germany & German Cancer Consortium (Deutsches Konsortium für Translationale Krebsforschung, DKTK), Essen, Germany.
Elisabeth LivingstoneDepartment of Dermatology, University Hospital Essen, University of Duisburg-Essen, Germany & German Cancer Consortium (Deutsches Konsortium für Translationale Krebsforschung, DKTK), Essen, Germany.
Lisa ZimmerDepartment of Dermatology, University Hospital Essen, University of Duisburg-Essen, Germany & German Cancer Consortium (Deutsches Konsortium für Translationale Krebsforschung, DKTK), Essen, Germany.
Eva HadaschikDepartment of Dermatology, University Hospital Essen, University of Duisburg-Essen, Germany & German Cancer Consortium (Deutsches Konsortium für Translationale Krebsforschung, DKTK), Essen, Germany.
Selma UgurelDepartment of Dermatology, University Hospital Essen, University of Duisburg-Essen, Germany & German Cancer Consortium (Deutsches Konsortium für Translationale Krebsforschung, DKTK), Essen, Germany.
Dirk SchadendorfDepartment of Dermatology, University Hospital Essen, University of Duisburg-Essen, Germany & German Cancer Consortium (Deutsches Konsortium für Translationale Krebsforschung, DKTK), Essen, Germany.
Carl Maximilian Thielmann *Department of Dermatology, University Hospital Essen, University of Duisburg-Essen, Germany & German Cancer Consortium (Deutsches Konsortium für Translationale Krebsforschung, DKTK), Essen, Germany.
Klaus Georg Griewank *Department of Dermatology, University Hospital Essen, University of Duisburg-Essen, Germany & German Cancer Consortium (Deutsches Konsortium für Translationale Krebsforschung, DKTK), Essen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Screening for gene mutations has become routine clinical practice across numerous tumor entities, including melanoma. Methods: A retrospective analysis of all melanomas sequenced in our department from 2014-2022 (n=2650) was conducted to identify Results: Conclusion: In contrast to uveal melanomas, where

Indexed as

MelanomaMutationTumor Suppressor ProteinsUbiquitin ThiolesteraseUveal NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesUveal MelanomaBAP1 protein, humanTumor Suppressor ProteinsUbiquitin ThiolesteraseBAP1immunotherapymutation profilingnon-uveal melanomauveal melanoma

Identifiers

PMID38903495
PMCPMC11188379

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.